Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
GlucoTrack ( (GCTK) ) just unveiled an update.
Glucotrack, Inc. announced its participation at the TechBio Showcase 2025, where its President and CEO, Paul V. Goode, will present an update on the company’s Continuous Blood Glucose Monitor (CBGM). This event is part of the Biotech Showcase, a major investor conference that fosters networking and partnership opportunities in the biotechnology and life sciences sectors. The presentation could enhance Glucotrack’s visibility and potentially attract investments, thereby strengthening its position in the diabetes care market.
More about GlucoTrack
Glucotrack, Inc. (NASDAQ: GCTK) is a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system.
YTD Price Performance: -51.56%
Average Trading Volume: 1,796,832
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.56M
See more data about GCTK stock on TipRanks’ Stock Analysis page.
Trending Articles
- 3 Penny Stocks to Watch Now, 1/9/25
- M&A News: Arm Holdings Explores Possible Takeover of Ampere Computing
- M&A News: Constellation Energy’s $30B Calpine Takeover Takes Shape
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
